Abstract |
The clinical effect of gatifloxacin (GFLX) at 200 mg daily (half of common dosage) on bacterial community-acquired pneumonia in the elderly was examined. Subjects were 30 patients with bacterial community-acquired pneumonia aged 65 years or more (mild, 21 patients; moderate, 9 patients), and GFLX at 100 mg per dose was administered twice daily for 4-14 days. The results included clinical effectiveness in 21 of 21 mildly affected patients (efficacy rate, 100%), in 8 of 9 moderately affected patients (efficacy rate, 88.9%), and 29 of a total of 30 patients (efficacy rate, 96.7%). With regard to bacteriological effect, 28 of 29 strains were eradicated (eradication rate, 96.6%). Abnormal laboratory findings included mild elevations in GPT, GOT, and ALP in only 1 patient. Based on these findings, we concluded that administration of GFLX at 200 mg daily is recommended for bacterial community-acquired pneumonia in the elderly.
|
Authors | Niro Okimoto, Takashi Kibayashi, Kimihiro Mimura, Kenji Yamato, Takeyuki Kurihara, Yoshihiro Honda, Kohichi Osaki, Naoko Asaoka, Hideo Ohba |
Journal | Journal of infection and chemotherapy : official journal of the Japan Society of Chemotherapy
(J Infect Chemother)
Vol. 11
Issue 6
Pg. 274-7
(Dec 2005)
ISSN: 1341-321X [Print] Netherlands |
PMID | 16369733
(Publication Type: Clinical Trial, Journal Article)
|
Chemical References |
- Anti-Infective Agents
- Fluoroquinolones
- Gatifloxacin
|
Topics |
- Aged
- Aged, 80 and over
- Anti-Infective Agents
(administration & dosage, adverse effects, therapeutic use)
- Community-Acquired Infections
(drug therapy, microbiology)
- Female
- Fluoroquinolones
(administration & dosage, adverse effects, therapeutic use)
- Gatifloxacin
- Gram-Negative Bacteria
(drug effects)
- Gram-Positive Bacteria
(drug effects)
- Humans
- Male
- Microbial Sensitivity Tests
- Pneumonia, Bacterial
(drug therapy, microbiology)
- Severity of Illness Index
- Treatment Outcome
|